NCT06893796 - Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 26, 2025

Primary Completion Date

May 8, 2025

Study Completion Date

May 8, 2025

Conditions

Preeclampsia

Interventions

DRUG

Telpegfilgrastim Injection

Telpegfilgrastim Injection,0.25mg, s.c.,day 1 single dose .

DRUG

Telpegfilgrastim Injection

Telpegfilgrastim Injection,0.5mg, s.c.,day 1 single dose .

DRUG

Telpegfilgrastim Injection

Telpegfilgrastim Injection,1mg, s.c.,day 1 single dose .

Trial Locations (1)

Peking University Third Hospital, Beijing

All Listed Sponsors

collaborator

Peking University Third Hospital

OTHER

lead

Xiamen Amoytop Biotech Co., Ltd.

INDUSTRY